PDF(Pubmed)
Abstract：
UNASSIGNED: New obesity medications result in large weight losses. However, long-term adherence in a real-world setting is challenging, and termination of obesity medication results in weight regain towards pre-treatment body weight. Therefore, we investigated whether weight loss and improved body composition are sustained better at 1 year after termination of active treatment with glucagon-like peptide-1 (GLP-1) receptor agonist, supervised exercise program, or both combined for 1 year.
UNASSIGNED: We conducted a post-treatment study in extension of a randomised, controlled trial in Copenhagen. Adults with obesity (aged 18-65 years and initial body mass index 32-43 kg/m2) completed an eight-week low-calorie diet-induced weight loss of 13.1 kg (week -8 to 0) and were randomly allocated (1:1:1:1) to one-year weight loss maintenance (week 0-52) with either supervised exercise, the GLP-1 receptor agonist once-daily subcutaneous liraglutide 3.0 mg, the combination of exercise and liraglutide, or placebo. 166 Participants completed the weight loss maintenance phase. All randomised participants were invited to participate in the post-treatment study with outcome assessments one year after treatment termination, at week 104. The primary outcome of the post-treatment assessment was change in body weight from after the initial weight loss (at randomisation, week 0) to one year after treatment termination (week 104) in the intention-to-treat population. The secondary outcome was change in body-fat percentage (week 0-104). The study is registered with EudraCT, 2015-005585-32, and with ClinicalTrials.gov, NCT04122716.
UNASSIGNED: Between Dec 17, 2018, and Dec 17, 2020, 109 participants attended the post-treatment study. From randomisation to one year after termination of combined exercise and liraglutide treatment (week 0-104), participants had reduced body weight (-5.1 kg [95% CI -10.0; -0.2]; P = 0.040) and body-fat percentage (-2.3%-points [-4.3 to -0.3]; P = 0.026) compared with after termination of liraglutide alone. More participants who had previously received combination treatment maintained a weight loss of at least 10% of initial body weight one year after treatment termination (week -8 to 104) compared with participants who had previously received placebo (odds ratio [OR] 7.2 [2.4; 21.3]) and liraglutide (OR 4.2 [1.6; 10.8]). More participants who had previously received supervised exercise maintained a weight loss of at least 10% compared with placebo (OR 3.7 [1.2; 11.1]). During the year after termination of treatment (week 52-104), weight regain was 6.0 kg [2.1; 10.0] larger after termination of liraglutide compared with after termination of supervised exercise and 2.5 kg [-1.5 to 6.5] compared with after termination of combination treatment.
UNASSIGNED: The addition of supervised exercise to obesity pharmacotherapy seems to improve healthy weight maintenance after treatment termination compared with treatment termination of obesity pharmacotherapy alone. Body weight and body composition were maintained one year after termination of supervised exercise, in contrast to weight regain after termination of treatment with obesity pharmacotherapy alone.
UNASSIGNED: Helsefonden and the Novo Nordisk Foundation.
UNASSIGNED: We conducted a post-treatment study in extension of a randomised, controlled trial in Copenhagen. Adults with obesity (aged 18-65 years and initial body mass index 32-43 kg/m2) completed an eight-week low-calorie diet-induced weight loss of 13.1 kg (week -8 to 0) and were randomly allocated (1:1:1:1) to one-year weight loss maintenance (week 0-52) with either supervised exercise, the GLP-1 receptor agonist once-daily subcutaneous liraglutide 3.0 mg, the combination of exercise and liraglutide, or placebo. 166 Participants completed the weight loss maintenance phase. All randomised participants were invited to participate in the post-treatment study with outcome assessments one year after treatment termination, at week 104. The primary outcome of the post-treatment assessment was change in body weight from after the initial weight loss (at randomisation, week 0) to one year after treatment termination (week 104) in the intention-to-treat population. The secondary outcome was change in body-fat percentage (week 0-104). The study is registered with EudraCT, 2015-005585-32, and with ClinicalTrials.gov, NCT04122716.
UNASSIGNED: Between Dec 17, 2018, and Dec 17, 2020, 109 participants attended the post-treatment study. From randomisation to one year after termination of combined exercise and liraglutide treatment (week 0-104), participants had reduced body weight (-5.1 kg [95% CI -10.0; -0.2]; P = 0.040) and body-fat percentage (-2.3%-points [-4.3 to -0.3]; P = 0.026) compared with after termination of liraglutide alone. More participants who had previously received combination treatment maintained a weight loss of at least 10% of initial body weight one year after treatment termination (week -8 to 104) compared with participants who had previously received placebo (odds ratio [OR] 7.2 [2.4; 21.3]) and liraglutide (OR 4.2 [1.6; 10.8]). More participants who had previously received supervised exercise maintained a weight loss of at least 10% compared with placebo (OR 3.7 [1.2; 11.1]). During the year after termination of treatment (week 52-104), weight regain was 6.0 kg [2.1; 10.0] larger after termination of liraglutide compared with after termination of supervised exercise and 2.5 kg [-1.5 to 6.5] compared with after termination of combination treatment.
UNASSIGNED: The addition of supervised exercise to obesity pharmacotherapy seems to improve healthy weight maintenance after treatment termination compared with treatment termination of obesity pharmacotherapy alone. Body weight and body composition were maintained one year after termination of supervised exercise, in contrast to weight regain after termination of treatment with obesity pharmacotherapy alone.
UNASSIGNED: Helsefonden and the Novo Nordisk Foundation.
摘要：
■新的肥胖药物导致大量的体重减轻。然而,在现实世界中的长期坚持是具有挑战性的，终止肥胖药物治疗会导致体重恢复到治疗前的体重。因此,我们调查了在停止胰高血糖素样肽-1（GLP-1）受体激动剂积极治疗后1年，体重减轻和身体成分改善是否持续得更好，监督锻炼计划，或两者合并1年。
■我们进行了一项治疗后研究，哥本哈根的对照试验。患有肥胖症的成年人（年龄在18-65岁，初始体重指数为32-43kg/m2）完成了为期八周的低热量饮食诱导的体重减轻13.1kg（第8至0周），并随机分配（1：1：1：1：1）进行为期一年的减肥维持（第0-52周），GLP-1受体激动剂每日一次皮下利拉鲁肽3.0mg，运动和利拉鲁肽的结合，或安慰剂。166名参与者完成了减肥维持阶段。邀请所有随机参与者参加治疗后研究，并在治疗终止后一年进行结果评估。104周治疗后评估的主要结果是初始体重减轻后的体重变化（随机分组时，第0周)至治疗终止后一年(第104周)的意向治疗人群。次要结果是体脂百分比的变化（0-104周）。这项研究在EudraCT注册，2015-005585-32，并与ClinicalTrials.gov，NCT04122716。
■在2018年12月17日至2020年12月17日之间，有109名参与者参加了治疗后研究。从随机分组到运动和利拉鲁肽联合治疗终止后一年（第0-104周），与利拉鲁肽单药终止后相比,参与者的体重降低(-5.1kg[95%CI-10.0;-0.2];P=0.040)和体脂百分比降低(-2.3%-分[-4.3~-0.3];P=0.026).与先前接受过安慰剂（比值比[OR]7.2[2.4;21.3]）和利拉鲁肽（OR4.2[1.6;10.8]）的参与者相比，更多先前接受过联合治疗的参与者在治疗终止后一年（第-8周至第104周）保持了初始体重的至少10％的体重减轻。与安慰剂相比，更多以前接受有监督运动的参与者的体重减轻至少10％（OR3.7[1.2;11.1]）。在治疗终止后的一年（第52-104周），与终止有监督的运动后相比,终止利拉鲁肽后的体重恢复为6.0kg[2.1;10.0],与终止联合治疗后的体重恢复为2.5kg[-1.5~6.5].
■与单独的肥胖药物治疗终止治疗相比，在肥胖药物治疗中添加有监督的运动似乎可以改善治疗终止后的健康体重维持。在监督运动终止一年后，体重和身体成分保持不变，与单纯肥胖药物治疗终止后体重恢复相反.
■赫尔塞丰登和诺和诺德基金会。
■我们进行了一项治疗后研究，哥本哈根的对照试验。患有肥胖症的成年人（年龄在18-65岁，初始体重指数为32-43kg/m2）完成了为期八周的低热量饮食诱导的体重减轻13.1kg（第8至0周），并随机分配（1：1：1：1：1）进行为期一年的减肥维持（第0-52周），GLP-1受体激动剂每日一次皮下利拉鲁肽3.0mg，运动和利拉鲁肽的结合，或安慰剂。166名参与者完成了减肥维持阶段。邀请所有随机参与者参加治疗后研究，并在治疗终止后一年进行结果评估。104周治疗后评估的主要结果是初始体重减轻后的体重变化（随机分组时，第0周)至治疗终止后一年(第104周)的意向治疗人群。次要结果是体脂百分比的变化（0-104周）。这项研究在EudraCT注册，2015-005585-32，并与ClinicalTrials.gov，NCT04122716。
■在2018年12月17日至2020年12月17日之间，有109名参与者参加了治疗后研究。从随机分组到运动和利拉鲁肽联合治疗终止后一年（第0-104周），与利拉鲁肽单药终止后相比,参与者的体重降低(-5.1kg[95%CI-10.0;-0.2];P=0.040)和体脂百分比降低(-2.3%-分[-4.3~-0.3];P=0.026).与先前接受过安慰剂（比值比[OR]7.2[2.4;21.3]）和利拉鲁肽（OR4.2[1.6;10.8]）的参与者相比，更多先前接受过联合治疗的参与者在治疗终止后一年（第-8周至第104周）保持了初始体重的至少10％的体重减轻。与安慰剂相比，更多以前接受有监督运动的参与者的体重减轻至少10％（OR3.7[1.2;11.1]）。在治疗终止后的一年（第52-104周），与终止有监督的运动后相比,终止利拉鲁肽后的体重恢复为6.0kg[2.1;10.0],与终止联合治疗后的体重恢复为2.5kg[-1.5~6.5].
■与单独的肥胖药物治疗终止治疗相比，在肥胖药物治疗中添加有监督的运动似乎可以改善治疗终止后的健康体重维持。在监督运动终止一年后，体重和身体成分保持不变，与单纯肥胖药物治疗终止后体重恢复相反.
■赫尔塞丰登和诺和诺德基金会。
